— Studies in B cell and T cell lymphoma models suggest Hyleukin-7TM can significantly enhance and prolong CAR-T activity —
ROCKVILLE, Md. – December 3, 2018–NeoImmuneTech, Inc., an immunotherapy drug development company focused on advanced cancer treatments, today announced the presentation of two preclinical studies supporting the potential of combining Hyleukin-7TMTM with Universal CAR-T (UCART) treatment to enhance and prolong the activity of allogeneic “off-the-shelf” adoptive immunotherapy for the treatment of B cell and T cell lymphomas. The data were presented in an oral presentation and a poster session at the 60th American Society of Hematology Annual Meeting and Exposition in San Diego, CA.
The two studies, conducted in collaboration with researchers from Washington University in St. Louis, evaluated the effects that Hyleukin-7TM, a long-acting T cell amplifier, had in combination with different types of UCART treatments. The researchers evaluated Hyleukin-7TM’s effects on proliferation, differentiation and tumor killing capacity of UCARTs in tumor models of B cell lymphoma and T cell lymphoma. The T cell lymphoma model was a physiologically-relevant patient-derived xenograft (PDX) mouse model of Sézary syndrome (SS), an aggressive and highly-morbid cutaneous T cell lymphoma with no widely-effective treatments.
Hyleukin-7TM was shown to dramatically enhance UCART proliferation, persistence and tumor killing in vivo, resulting in enhanced survival in both models. Furthermore, the results suggest that the addition of Hyleukin-7TM dramatically increased the activity of UCART treatment and could provide a tunable, clinic-ready “enabling therapy” for suboptimal CART activity in vivo.
“NeoImmuneTech’s Hyleukin-7TM has broad potential to strengthen our immune system in its battle against both foreign invaders as well as enemies within, adding a therapeutic effect wherever the body’s T cells are weak or in low numbers,” said Se Hwan Yang, Ph.D., Chief Executive Officer of NeoImmuneTech. “These latest experiments in lymphoma models show that Hyleukin-7TM may also strengthen and prolong the effects of T cell therapies, such as CAR-T. The beneficial effects of Hyleukin-7TM when combined with UCART are highly encouraging, as developing an effective, off-the-shelf and universal CAR-T therapeutic is a major goal for immuno-oncology drug developers. NeoImmuneTech’s main focus is advancing our clinical trials with Hyleukin-7TM as efficiently as possible so that we can ultimately deliver it in a timely manner to patients in need.”
Dr. John F. DiPersio, M.D., Ph.D., Chief, Division of Oncology and Deputy Director of the Alvin J. Siteman Cancer Center at Barnes-Jewish Hospital and Washington University School of Medicine added: “CAR-T therapies hold a great promise for cancer patients, as well as for other diseases. We have made incredible steps toward creating a universal CAR-T that would highly increase the percent of people that can benefit from this technology, while significantly decreasing the time to treatment and the cost of production. However, a major hurdle that still remains for both current and future CAR-T treatments is the short effective period for these cells in the body. Hyleukin-7TM has the potential to boost both the time and the effectivity of CAR-T treatments, and we are looking forward to the continued clinical development of this drug candidate.”Presentation Details: